DUSA Notified of Queen's University Australian Patent Challenge.Business Editors WILMINGTON, Mass.--(BUSINESS WIRE)--April 15, 2002 DUSA DUSA Deputy Under Secretary of the Army DUSA Deakin University Student Association DUSA Dundee University Students' Association (Scotland) DUSA Designated Unclassified Subject Area Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on NMS See NetWare Management System. : DUSA) reports that it received notice on Friday that one of the patents licensed to DUSA by PARTEQ Research & Development Innovations, the technology transfer arm of Queen's University at Kingston Queen's University at Kingston Privately endowed university in Kingston, Ontario, Canada. It was founded in 1841 and modeled after the University of Edinburgh. It is a comprehensive research institution, offering undergraduate, graduate, and professional degrees in most , Ontario is being challenged by PhotoCure ASA Asa (ā`sə), in the Bible, king of Judah, son and successor of Abijah. He was a good king, zealous in his extirpation of idols. When Baasha of Israel took Ramah (a few miles N of Jerusalem), Asa bought the help of Benhadad of Damascus and . PhotoCure has filed a lawsuit in Australia alleging that Australian Patent No. 624985, which is one of the patents relating to DUSA's 5-aminolevulinic acid technology, is invalid. DUSA intends to evaluate the situation with Queen's and PARTEQ, as PARTEQ has an obligation to diligently maintain its patents under its license agreement with DUSA. DUSA Pharmaceuticals, Inc. is a biopharmaceutical company engaged primarily in the development of Levulan(R) Photodynamic Therapy (PDT) and Photodetection (PD) for multiple medical indications. PDT and PD utilize light-activated compounds such as Levulan(R) to induce a therapeutic or detection effect. DUSA is a world leader in topically or locally applied PDT and PD. The Company maintains offices in Wilmington, MA, Valhalla, NY, and Toronto, Ontario. Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements relate to intentions to review the action with Queen's and PARTEQ. The risks associated with these statements include the relationship of DUSA with Queen's University and PARTEQ, risks of litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and other risks identified in DUSA's SEC filings from time to time, including its Form 10-K for the year ended December 31, 2001. For further information contact: D. Geoffrey Shulman, MD, President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. or Shari Lovell, Director, Shareholder Services Tel: 416.363.5059 Fax: 416.363.6602 or visit www.dusapharma.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion